Skip to main content

Table 1 Biological, cytogenetic, and molecular characteristics of HD, MDS, and AML patients

From: Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival

Patient ID

Cytogenetics

Molecular

Gender

Age (years)

Risk

MSCs/MNCs

Cytogenetic alteration in MSCs

AML01

46,XX,t(6;9)

(p22;q34)[20]a

NPMwt

FLT3-ITD

Female

45

Highb

0.97

ND

AML02

46,XY[20]

ND

Male

80

Intermediate

ND

ND

AML03

46,XY[20]

NPMmut FLT3wt

Male

63

Low

1.5

ND

AML04

46,XY,inv(16)

(p13q22)[20]

NPMwt

FLT3wt

TP53wt

Male

55

Low

0.1

Negative

AML05

46,XX[20]

NPMmut. FLT3wt

TP53wt

Female

63

Low

ND

ND

AML06 c

ND

NPMmut

FLT3-ITD TP53wt

Male

70

Intermediate

ND

ND

AML07

46,XY,t(15;17)

(q22;q22)[20]

ND

Male

39

NA

0.2

Negative

AML08

46,XX[20]

NPMmut FLT3-ITD/TKD

Female

47

Intermediate

1.3

ND

AML09

46,XX[20]

NPMmut

FLT3-ITD

Female

61

Intermediate

0.7

ND

AML10

47,XY,+ 8[20]

NPMwt FLT3wt

Male

68

Intermediate

ND

ND

AML11

46,XY[20]

NPMmut

FLT3-ITD TP53wt

Male

73

Intermediate

ND

ND

AML12

47,XY,+der(3)

del(3)(p11),

t(10;11;19) (p12;q23;q13)[20]

NPMwt FLT3wt

Male

17

High

ND

Negative

AML13

44,XX,+der(3)

t(3;20)(p12;p11),del(5)(q13q33),

−7,–13,t(13;20)

(q12;p11),

−17,der(21)

t(17;21)

(q11;q22),

+mar[14]/

45,XX,t(1;16)

(q12;q11),del(5)

(q13q33),del(6)

(q21q25),

− 7,add(22)(q13)[6]

NPMwt

FLT3wt

TP53mut

Female

60

High

0.3

ND

AML14

46,XX,t(16;16)

(p13;q22)[20]

NPMwt. FLT3wt

TP53wt

Female

46

Low

ND

ND

AML15

46,XY,t(6;11)

(q27;q23)[20]

NPMwt FLT3wt

TP53wt

Male

19

High

5.6

ND

AML16

46,XY,inv(16)

(p13q22)[18]/

47,XY,inv(16)

(p13q22),+ 22[2]

NPMwt

FLT3wt

TP53wt

Male

26

Low

ND

ND

AML17

46,XX,t(9;11)

(p22;q23) [20]

NPMwt

FLT3wt

Female

55

Intermediate

0.1

ND

AML18

47,XX,+X,

add(7)(q34)[19]/

47,XX,+X[1]

ND

Female

72

Intermediate

ND

ND

AML19

46,XX[20]

FLT3-ITD

Female

61

High

6.9

ND

AML20

46,XX[20]

FLT3-ITD

Female

73

High

0.5

ND

AML21

47,XX,del(5)

(q22q33),+ 8[20]

ND

Female

62

High

ND

ND

AML22

46,XY[20]

FLT3-ITD

Male

79

High

6.4

ND

AML23

46,XX[20]

NPMmut FLT3-TKD

Female

76

Low

5.6

ND

AML24

46,XX,der(4)

t(1;4)(q32;q31)

[20]

NPMwt FLT3wt

TP53wt

Female

55

Intermediate

3.7

ND

AML25

46,XY[20]

NPMwt FLT3-ITD TP53wt

Male

31

Intermediate

ND

ND

AML26

ND

NPMwt

FLT3wt

TP53wt

Male

57

NA

0.5

ND

AML27

ND

NPMmut

FLT3wt

TP53wt

Male

59

Low

ND

ND

AML28

46,XY,–7,+ 21[20]

NPMwt

FLT3wt

TP53wt

Male

74

High

ND

ND

AML29

46,XX[20]

NPMwt FLT3wt TP53wt

Male

69

Intermediate

ND

ND

AML30

47,XY,inv(16)

(p13q22),+ 8[14]/46,XY,inv.(16) (p13q2)[6]

NPMwt

FLT3wt TP53wt

Male

56

Low

ND

ND

AML31

46,XY,t(6;9)

(p22;q34)[20]

NPMwt

FLT3-ITD

Male

75

Intermediate

3.2

ND

AML32

ND

ND

Female

71

ND

ND

ND

MDS1

46,XX[20]

 

Female

79

Low/intermediated

0.8

ND

MDS3

46,XY[20]

 

Male

62

Int2/High

ND

ND

MDS4

46,XY[20]

 

Male

78

Int1/Low

0.5

ND

MDS5

46,XY[20]

 

Male

86

Low/Low

3.3

ND

MDS6

46,XX[20]

 

Female

61

High/High

2.7

ND

MDS9

46,XY[20]

 

Male

79

Low/Low

1.2

ND

MDS11

46,XY,del(20)

(q11q13)[20]

 

Male

53

Int1/intermediate

ND

ND

MDS12

71–74,XXX,

+der(2)t(2;17)

(p11;p12),

del(5)(q13q33), +der(5)del(5)

(q13q33),

−7[5]/46,XX[5]

 

Female

73

High/high

6.7

Negative

MDS15

46,XX,del(5)

(q13q33)[5]/

46,XX,

del(5)(q13q33),

del(11)(q21q25)

[3]

 

Female

76

Int1/Low

5.6

ND

MDS16

46,XY[20]

 

Male

80

Low/low

2.6

ND

MDS17

46,XY[20]

 

Male

68

High/very high

6

ND

MDS18

46,XY[20]

 

Male

66

Low/low

8.3

ND

MDS21

46,XY[20]

 

Male

78

Low/low

ND

ND

MDS22

46,XY[30]e

 

Male

61

Low/low

4.4

ND

MDS24

46,XX[20]

 

Female

83

Low/low

2.5

ND

MDS25

46,XX,del(20)

(q11q13)[20]

 

Female

81

Low/low

ND

ND

MDS26

46,XY[20]

 

Male

54

Low/low

8.9

ND

MDS32

46,XX[20]

 

Female

67

Low/low

2.5

ND

MDS33

ND

 

Male

76

Int1/high

3.6

ND

MDS34

46,XY[20]

 

Male

90

Int1/low

3.5

ND

MDS35

46,XX[20]

 

Female

83

Low/low

2.5

ND

MDS36

47,XY,+ 8[20]

 

Male

82

Int2/very high

1.8

ND

MDS38

46,X,idic(X)

(q13)[16]/45,X,

–X[2]/47,X,

del(X)(q13),

+idic(X)(q13)

[1]/47,del(X) (q13),idic(X)

(q13) + idic(X)

(q13)[1]

 

Female

86

Int1/low

1.1

ND

MDS39

46,XY[20]

 

Male

87

Int1/intermediate

ND

ND

MDS43

49,XY,+ 1,del(5)

(q13q33),

+der(5)del(5)

(q13q33),

+ 11[18]/47XY,

del(5)(q13q33),

+der(5)del(5)

(q13q33)[1]/

46XY,del(5)

(q13q33)[1]

 

Male

79

Int2/high

ND

Negative

MDS45

46,XY,del(13)

(q12q14)[3]/

46,XY[17]

 

Male

65

High/very high

ND

Negative

HD01

46,XY

Male

22

ND

ND

HD02

46,XY

Male

19

ND

ND

HD03

46,XY

Male

43

8.4

ND

HD04

46,XY

Male

44

2.2

ND

HD05

46,XY

Male

32

5.4

ND

HD06

46,XY

Male

41

2

ND

HD07

46,XX

Female

62

0.5

ND

HD08

46,XY

Male

60

14.3

ND

HD09

46,XX

Female

43

9.4

ND

HD10

46,XX

Female

52

7

ND

HD11

46,XY

Male

22

11.2

ND

HD12

46,XY

Male

38

ND

ND

  1. AML acute myeloid leukemia, HD healthy donor, MDS myelodysplastic syndrome, MNC mononuclear seeded cell, MSC mesenchymal stromal cell, ND not determined, int1 intermediate 1 risk, int2 intermediate 2 risk
  2. aKaryotypes described according to the International System for Human Cytogenetic Nomenclature (ISCN 2016) [53, 54]
  3. bRisk evaluation following ELN 2017 [55]
  4. cPatients in which MSCs were not isolated are indicated in italics
  5. dRisk evaluation following IPSS/IPSS-R [56, 57]
  6. eCEP 8 spectrum orange DNA probe shows 3 signals in 4% of interphase nuclei